EUCTR2008-003538-11-FR进行中（未招募）1 期
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II).
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Chronic hepatitis C infection, diagnosed by seropositivity for anti-HCV antibodies or detectable HCV RNA at least 6 months prior to screening
- •2)HCV infection of genotype 1(1a, 1b or mixed 1a/1b) diagnosed by genotypic testing or screening
- •3)Therapy-naive to interferon (including any experimental or investigational interferon products as monotherapy or in combination with any other agents), pegylated interferon, or ribavirin for acute or chronic hepatitis C infection
- •4)HCV viral load>=100.000 IU/mL at screening
- •5) Exclusion of liver cirrhosis by fibroscan or liver biopsy wihtin 24 months prior to study enrolment
- •6)Age 18 to 65
- •7)Female patients (a)with documented hysterectomy, or (b) who have had both ovaries removed, or (c) with documented tubal ligation, or (d) who are post-menopausal with last menstrual period at least 12 months prior to screening, or
- •(e) childbearing potenital with a negativ serum pregnancy test at screening and on Day 1 (Visit 2) that either agree to abstain from intercourse, or agree to use one of the appropriate medically accepted methods of birth control (see below) from the date of scrreening until 6 months after the last dose of ribavirin in addition to the consistent and correct use of a condom, and that are not breats-feeding or nursing or plan to nurse at any time from the date of screening until 6 months after the last dose of ribavirin.
- •Note : Pregnancy tests must be performed every 4 weeks after screening until 6 months after the last dose of ribavirin for females of childbearing potential. Note: Medically accepted methods of contraception for females in this trial are ethinyl estradiol containing contraceptives, diaphragm with spermicide substance, and cervical cap.
- •8)Male patients (a) who are documented to be sterile, or (b) who agree to abstain from intercourse from the date of screening until 6 months after the last dose of ribavirin, or (c) who consistently and correctly use a condom while their female partners (if applicable) agree to use one of the appropriate medically accepted methods of birth control (see below) fro mthe date of screening until 6 months after the last dose of ribavirin, and (d) without pregnant female partners. It is in the responsibility of the male patient to ensure that his partner (or partners) is not pregnant prio to entry into the study or becomes pregnant during the treatment and follow-up phase. Female partners of childbearing potential must agree to perform a monthly pregnancy test from the date of screening until 6 months after the last dose of ribavirin
- •9)Signed informed consent from prior to trial participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Hepatitis C infection of mixed genotype diagnosed by genotypic testing at screening
- •2)Patients who have been previously treated with at least one dose of any protease inhibitor for acute or chronic hepatitis C infection
- •3)Evidence of liver disease due to causes other than chronic HCV infection
- •4)Positive ELISA for HIV-1 or HIV-2
- •5) Hepatitis B virus (HBV) infection based on presence of HBs-Ag
- •6) Decompensated liver disease, or history of decompensated liver disease, as evidenced by ascites, portal hypertension, jaundice or hepatic encephalopathy, coagulopathy, varices, history of variceal bleeding, or any other clincial evidence of decompensation
- •7) Active or suspected malignancy or history of malignancy within the last 5 years (with the exception of appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix)
- •8)History of alcohol or drug abuse within the past 12 months. Patients with documented drug and alcohol addiction free history of at least 12 months who are, in the opinion of the investigator, unlikely to relapse, may be enrolled in the study.
- •Note: Patients with a positive drug screen other than cannabis at time of screening will be excluded from the trial.
- •9)Usage of any investigational drugs within 30 days prior to enrolment, or 5 half-lives, whichever is longer; or the planned usage of an investigational drug during the course of the current study
- •10)Known hypersensitivity to any ingredient of the study drug
- •11)A condition that is defined as one which in the opinion of the investigator may either put the patient at risk because of participation in the study or may influence the results of the study or the patient's ability to participate in the study
- •12)Alpha fetoprotein value>100ng/mL at screening; if >20ng/mL and <=100ng/mL, patients can be included if there is no evidence of liver cancer in two congruent imaging studies (e.g., ultrasound, CT scan, MRI) within 6 months of Day 1
- •13)Total bilirubin >1.5xULN with ratio of direct/indirect > 1. (Patients with Gilbert's polymorphism are not excluded.)
- •14)ALT and AST levels >=5xULN
- •15)INR prolonged to >1.5xULN
- •16)Hemoglobin<12g/dL for women and <13g/dL for men
- •17)White blood cell count <2000cells/mm3
- •18)Absolute neutrophil count <1500cells/mm3
- •19)Platelet count<100.000cells/mm3
- •20)TSH and T4 outside normal limits and not adequately controlled thyroid function; patients with TSH below the lower limit of normal my be enrolled if free T4 is normal and there is no clinical evidence of hyperthyroidism or hypothyroidism
- •21)Poorly controlled diabetes mellitus as evidenced by HbA1c>7.5%
- •22)Patients who are at risk for bleeding (NSAIDs therapy, anticoagulant therapy, vitamin K deficiency, knwon coagulopathy, hemophilia)
- •23)Hemoglobinopathy (e.g. thalassemia major or sickle cell anemia)
- •24)History of moderate, severe or uncontrolled psychiatric disease, especially depression.
- •25)Clinical evidence of chronic cardiac disease
- •26)Clinically significant abnormalities on screening ECG
- •27)Clinical evidence of chronic pulmonary disease (e.g., chronic obstructive pulmonary disease) associated with functional impairment
- •28) Active autoimmune disease, including autoimmune hepatitis
- •29)Evidence of acute or chronic renal disease
- •30)Organ transplant history, other than cornea or hair
- •31)Abnormal retinal finding by fundoscopy within 6 months prior to Day1
- •32)Active seizure disorder within the past 2 years; patients may be enrolled if on stable medication and seizu
研究者
相似试验
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II)EUCTR2008-003538-11-CZBoehringer Ingelheim RCV GmbH & Co. KG700
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II)Proposed new title:Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double blinded, randomised, placebo controlled, Phase II)EUCTR2008-003538-11-PTBoehringer Ingelheim Pharma GmbH & Co. KG700
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II)chronic hepatitis C infection of genotype 1MedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-003538-11-NLBoehringer Ingelheim bv420
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II)Proposed new title:Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (double blinded, randomised, placebo controlled, Phase II)EUCTR2008-003538-11-ATBoehringer Ingelheim Pharma RCV GmbH & Co. KG700
进行中（未招募）
不适用
Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve and treatment-experienced patients for 24 weeks as combination therapy with pegylated interferon-a 2a and ribavirin (doubleblinded, randomised, placebo-controlled, Phase II).chronic hepatitis C infection of genotype 1MedDRA version: 14.0Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-003538-11-DEBoehringer Ingelheim Pharma GmbH & Co. KG700